Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy. (24th October 2020)

• Record Type: Journal Article
• Authors: Lim, Jasmine; Hinotsu, Shiro; Onozawa, Mizuki; Malek, Rohan; Sundram, Murali; Teh, Guan C.; Ong, Teng‐Aik; Thevarajah, Shankaran; Zainal, Rohana; Khoo, Say C.; Omar, Shamsuddin; Nasuha, Noor A.; Akaza, Hideyuki
• Is Part Of: Cancer medicine. Volume 9:Number 24(2020)
• Page Start: 9346
• Page End: 9352
• Publication Date: 2020-10-24
• Subjects: advanced prostate cancer -- overall survival -- progression‐free survival -- risk stratification -- treatment response; 616.994005
• DOI: 10.1002/cam4.3548
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The J‐CAPRA score is an assessment tool which stratifies risk and predicts outcome of primary androgen deprivation therapy (ADT) using prostate‐specific antigen, Gleason score, and clinical TNM staging. Here, we aimed to assess the generalisability of this tool in multi‐ethnic Asians. Performance of J‐CAPRA was evaluated in 782 Malaysian and 16, 946 Japanese patients undergoing ADT from the Malaysian Study Group of Prostate Cancer (M‐CaP) and Japan Study Group of Prostate Cancer (J‐CaP) databases, respectively. Using the original J‐CAPRA, 69.6% metastatic (M1) cases without T and/or N staging were stratified as intermediate‐risk disease in the M‐CaP database. To address this, we first omitted clinical T and N stage variables, and calculated the score on a 0–8 scale in the modified J‐CAPRA scoring system for M1 patients. Notably, treatment decisions of M1 cases were not directly affected by both T and N staging. The J‐CAPRA score threshold was adjusted for intermediate (modified J‐CAPRA score 3–5) and high‐risk (modified J‐CAPRA score ≥6) groups in M1 patients. Using J‐CaP database, validation analysis showed that overall survival, prostate cancer‐specific survival, and progression‐free survival of modified intermediate and high‐risk groups were comparable to those of original J‐CAPRA ( p > 0.05) with Cohen's coefficient of 0.65. Around 88% M1 cases from M‐CaP database were reclassified into high‐risk category. Modified J‐CAPRA scoring system is instrumental in risk assessment and treatment outcome prediction for M1 patients without T and/or N staging. Abstract : The modified J‐CAPRA scoring system is a risk assessment tool to predict the outcome of primary androgen deprivation therapy (ADT) based on Gleason score, prostate‐specific antigen, and clinical M stage alone. It is beneficial and applicable in stratifying the risk and predicting the treatment outcomes of M1 patients without T and/or N staging.